Epigenetics in Precision Medicine
- 1st Edition, Volume 30 - November 12, 2021
- Editor: Jose Luis Garcia-Gimenez
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 0 0 8 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 8 0 5 - 2
In recent years, knowledge of epigenetic mechanisms underlying disease onset and progression has proven crucial for the development of novel early diagnosis and prognosis bi… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn recent years, knowledge of epigenetic mechanisms underlying disease onset and progression has proven crucial for the development of novel early diagnosis and prognosis biomarkers for patient stratification and precision medicine. Epigenetics in Precision Medicine, a new volume in the Translational Epigenetics series, provides a thorough discussion and overview of current developments in clinical epigenetics with special emphasis on epigenetic biomarkers that can be used for clinical diagnosis, prognosis, patient stratification, and treatment monitoring. Disease types discussed include cancer, metabolic disorders, neurodegenerative diseases, bone disease, and immune-related disorders. The book examines the challenges of advancing epigenetics research and translating findings to the clinic and drug discovery in each of these areas, as well as current solutions; chapter authors discuss how to leverage epigenomic technologies, applications, and tools, such as next-generation sequencing, to discover new epigenetic biomarkers in disease and drug studies.
Epigenetics in Precision Medicine focuses on complex epigenetic mechanisms in several pathologies, and explores how epigenetics can power the advance of precision medicine, not only by improving in vitro diagnostic and prognostic tools, but by providing new therapeutic approaches to treat human disease.
- Provides a thorough grounding in epigenetics-driven precision medicine, with emphasis on developing and implementing early diagnosis and prognosis biomarkers, and supporting patient stratification
- Empowers researchers and clinicians to incorporate epigenetics in new disease research, drug discovery, and clinical practice
- Features chapter contributions from international leaders in the field
Human geneticists; human genomicists; translational researchers in genomic medicine, epigenetics, biochemistry, molecular biology, oncology, neurology, endocrinology, reproductive medicine, pulmonary medicine, gerontology and anti-aging medicine, pediatrics, and bioinformatics; life science researchers; biotechnologists; developmental biologists; clinicians and graduate students in the biosciences
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter 1: Perspectives and future directions of translational epigenetics in personalized and precision medicine
- Abstract
- Introduction
- Diagnostic, prognostic, and therapeutic applications of epigenetics in precision medicine
- Epigenetic-based therapies
- Conclusions and perspective
- Chapter 2: Translational epigenetics in precision medicine of colorectal cancer
- Abstract
- Introduction
- Potential epigenetic biomarkers for CRC
- Epigenetic-based IVD test for CRC
- Conclusions and future prospects
- Chapter 3: Epigenetics in precision medicine of breast cancer
- Abstract
- Introduction
- Epigenetics in breast carcinogenesis
- DNA methylation as a biomarker for breast cancer
- Histone posttranslational modifications as a biomarker for breast cancer
- ncRNAs as a biomarker for breast cancer
- Dietary epigenetic modulators in precision medicine of breast cancer
- Conclusions
- Glossary
- Chapter 4: Epigenetics and precision medicine in prostate cancer
- Abstract
- Acknowledgments
- Introduction
- Prostate cancer epigenetics
- Epigenetic therapies in prostate cancer
- Epigenetic biomarkers of treatment response
- Conclusion
- Chapter 5: Epigenetics and precision medicine in lung cancer
- Abstract
- Introduction
- Epigenetics of lung cancer
- Diagnostic, prognostic, and therapeutic applications of epigenetics in lung cancer
- Drug response and therapeutics
- Conclusions and perspective
- Chapter 6: Epigenetics and precision medicine in bone and soft tissue sarcomas
- Abstract
- Introduction
- Osteosarcoma
- Ewing sarcoma
- Undifferentiated pleomorphic sarcoma
- Synovial sarcoma
- Rhabdomyosarcoma
- Leiomyosarcoma
- Liposarcoma
- Malignant peripheral nerve sheath tumor
- Fibrosarcoma
- Conclusions
- Chapter 7: Epigenetics and precision medicine in skin diseases
- Abstract
- Introduction
- Inflammatory skin diseases
- Connective tissue diseases
- Skin neoplasms
- Conclusions
- Chapter 8: Epigenetic biomarker and drug development in gynecological cancers
- Abstract
- Cervical cancer
- Endometrial cancer
- Ovarian cancer
- Conclusion
- Chapter 9: Epigenetics in precision medicine of pancreatic cancer
- Abstract
- Introduction
- Epigenetics of pancreatic cancer
- Diagnostic, prognostic, and therapeutic applications of epigenetics in pancreatic cancer
- Conclusions and perspective
- Chapter 10: Epigenetics and personalized medicine of brain cancer
- Abstract
- Ethics approval and consent to participate
- Consent for publication
- Availability of data and material
- Competing interests
- Conflict of interest
- Funding
- Acknowledgments
- Introduction
- Epigenomics: An introduction
- Comprehending epigenetics
- Targeted and personalized therapies
- Conclusions
- Glossary
- Chapter 11: Epigenetics and precision medicine in diabetes and obesity prevention and management
- Abstract
- Introduction
- Routine diagnostic biomarkers for obesity and T2D
- Epigenetic regulation and disease
- Epigenetic mechanisms
- Precision medicine and epigenetic marks in metabolic disorders
- Future remarks and conclusion
- Chapter 12: Epigenetics in precision medicine of cardiovascular disease
- Abstract
- Cardiovascular disease
- Biomarkers
- Epigenetic biomarkers: Noncoding RNAs
- Most relevant noncoding RNA subclasses in the field of biomarkers
- Noncoding RNAs as diagnostic biomarkers of cardiovascular disease
- Noncoding RNAs as prognostic biomarkers of cardiovascular disease
- Noncoding RNAs in biomarker-guided therapy of cardiovascular disease
- Defining clinical phenotypes: Noncoding RNAs and decision tree learning
- Conclusions
- Chapter 13: Sperm epigenetics: The future of precision medicine in male infertility
- Abstract
- Disclosures
- Introduction
- Epigenetics: Background and history
- Histone posttranslational modifications
- DNA methylation
- Noncoding RNA
- Epigenetics and fertility
- Using epigenetic data in predictive modeling to identify and treat male fertility
- Conclusions and future perspective
- Chapter 14: Epigenetic in precision medicine in autoimmune and inflammatory-mediated disorders
- Abstract
- Introduction
- Epigenetic bases of autoimmune inflammatory-related diseases
- Conclusions and perspective
- Chapter 15: Epigenetics and precision medicine in allergic diseases
- Abstract
- Introduction
- Precision medicine in allergic diseases
- The epigenome as a target for personalized treatment
- Conclusions
- Chapter 16: Epigenetics in spine curvature disorders
- Abstract
- Introduction
- Epigenetics in bone metabolism associated to spine deformity
- DNA methylation
- Noncoding RNAs
- Role of miRNAs in AIS
- Role of miRNAs in DS
- Epigenetic biomarkers in scoliosis precision medicine
- DNA methylation biomarkers in AIS precision medicine
- miRNAs biomarkers in AIS precision medicine
- Conclusions and future prospects
- Chapter 17: Methylated circulating tumor DNA biomarkers for the blood-based detection of cancer signals
- Abstract
- Introduction
- The public health burden of cancer and the need for minimally invasive tests for cancer detection
- Circulating tumor DNA as a biomarker for the detection of cancer signals
- Choice of somatic sequence mutation or DNA methylation as ctDNA biomarkers
- Characteristics and composition of cfDNA and ctDNA
- ctDNA detection technologies
- Best preanalytical practices for obtaining high-quality cfDNA templates
- Blood collection and preanalytical variables
- Cell-free DNA isolation and quality control
- Sodium bisulfite conversion of cfDNA for DNA methylation analyses
- Cell-free DNA assay types
- Real-time PCR-based assays for targeted loci
- Next-generation sequencing (NGS)-based assays
- “Real-world” applications of cfDNA technology to the detection of cancer signals
- Early detection of cancer via population-based screening
- Development of multicancer screening test based on methylated ctDNA profiles
- The Galleri test by GRAIL Inc
- Application of ctDNA technology in oncology for the clinical management of cancer patients
- Utility of ctDNA testing for monitoring tumor burden in cancer patients
- Benefits of the detection of molecular residual disease, recurrence, and tumor burden in the setting of colorectal cancer
- Personalized NGS-based assay for the detection of minimal residual disease and cancer recurrence
- Methylated ctDNA test for the detection of minimal residual disease and recurrence of CRC
- Liquid biopsy
- Liquid biopsy for the prediction of response to treatment
- Conclusions and future directions
- Chapter 18: Dietary regulation of miRNA in precision medicine of lung cancer
- Abstract
- Introduction
- Biogenesis of miRNA
- Role of miRNA in lung cancer progression
- Role of miRNAs in lung cancer therapeutics
- Dietary regulation of miRNA in lung cancer
- Conclusion and future perspective
- Glossary
- Chapter 19: Epigenetic biomarkers in male infertility and its potential use in assisted reproductive technology
- Abstract
- Introduction
- Epigenetics in spermatogenesis and male infertility
- The potential of epigenetics to improve clinical management of male infertility
- Conclusions and future prospects
- Index
- No. of pages: 614
- Language: English
- Edition: 1
- Volume: 30
- Published: November 12, 2021
- Imprint: Academic Press
- Paperback ISBN: 9780128230084
- eBook ISBN: 9780323858052
JG
Jose Luis Garcia-Gimenez
Dr. Garcia-Gimenez is a Senior Researcher at the Consortium Center for Biomedical Network Research, the Spanish Institute of Health Carlos III (ISCIII), and the INCLIVA Biomedical Research Institute, in the Dept. of Physiology at the Medicine and Dentistry School at the University of Valencia, Spain. Dr. García-Giménez is founder and CEO of EpiDisease S.L. (Spin-Off of CIBER-ISCIII), which develops the technology based on the patent EP15382319.0, currently in national phases (USTPO, EPO, CIPO and SIPO). EpiDisease received NEOTEC funds from CDTI and the Seal of Excellence from the European Commission in the SME Instrument Phase II H2020. Dr. García-Giménez has received 7 scientific and entrepreneurship national and international awards, including the National Award for Young Entrepreneurs in 2013 (awarded by the Spanish Ministry of Health) and the European Young Researcher from the Free Radical Research Society in 2009 and more recently the Eureka Innovation and Entrepreneurship Award in Melbourne (Australia). Dr. Garcia-Gimenez is a researcher at the University of Valencia. He is early in his career, but has been noticed as an up-and-coming authority in epigenetic biomarker research as it relates to disease, stress, and exercise.
Affiliations and expertise
CIBER Enfermedades Raras, Centre for Biomedical Research on Rare Diseases, University of Valencia, SpainRead Epigenetics in Precision Medicine on ScienceDirect